Majid Marjani to Humans
This is a "connection" page, showing publications Majid Marjani has written about Humans.
Connection Strength
0.056
-
The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality. Sci Rep. 2021 09 02; 11(1):17594.
Score: 0.008
-
Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. Iran J Allergy Asthma Immunol. 2021 Aug 07; 20(4):394-401.
Score: 0.008
-
Immune cell profiling and antibody responses in patients with COVID-19. BMC Infect Dis. 2021 Jul 05; 21(1):646.
Score: 0.008
-
Increased Serum Levels of Soluble TNF-a Receptor Is Associated With ICU Mortality in COVID-19 Patients. Front Immunol. 2021; 12:592727.
Score: 0.002
-
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021 Apr 15; 897:173947.
Score: 0.002
-
Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. Int Arch Allergy Immunol. 2021; 182(3):254-262.
Score: 0.002
-
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. Int Immunopharmacol. 2021 Apr; 93:107407.
Score: 0.002
-
Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. Hum Antibodies. 2021; 29(2):109-113.
Score: 0.002
-
Combination therapy of IFNß1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. Int Immunopharmacol. 2021 Mar; 92:107329.
Score: 0.002
-
Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology. 2021 Nov-Dec; 27(6):486-492.
Score: 0.002
-
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021 Jan; 90:107205.
Score: 0.002
-
Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients. Pathol Res Pract. 2020 Oct; 216(10):153228.
Score: 0.002
-
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
Score: 0.002
-
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. J Clin Immunol. 2020 10; 40(7):974-976.
Score: 0.002
-
Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. Immunol Invest. 2021 Nov; 50(8):884-890.
Score: 0.002
-
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
Score: 0.002
-
Diagnostic accuracy of interferon (IFN)-? inducible protein 10 (IP-10) as a biomarker for the discrimination of active and latent tuberculosis. Mol Biol Rep. 2019 Dec; 46(6):6263-6269.
Score: 0.002
-
An adult autosomal recessive chronic granulomatous disease patient with pulmonary Aspergillus terreus infection. BMC Infect Dis. 2018 Nov 08; 18(1):552.
Score: 0.002
-
miR-1224 Expression Is Increased in Human Macrophages after Infection with Bacillus Calmette-Guérin (BCG). Iran J Allergy Asthma Immunol. 2018 Jun; 17(3):250-257.
Score: 0.002
-
Risk factors for mortality among tuberculosis patients co-infected with HIV. Infect Dis (Lond). 2018 05; 50(5):399-402.
Score: 0.001
-
Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. J Glob Antimicrob Resist. 2017 12; 11:116-119.
Score: 0.001
-
Paecilomyces formosus Infection in an Adult Patient with Undiagnosed Chronic Granulomatous Disease. J Clin Immunol. 2017 05; 37(4):342-346.
Score: 0.001